247 110

Full metadata record

DC FieldValueLanguage
dc.contributor.author정윤양-
dc.date.accessioned2018-12-06T04:18:08Z-
dc.date.available2018-12-06T04:18:08Z-
dc.date.issued2016-09-
dc.identifier.citationJOURNAL OF BREAST CANCER, v. 19, no. 3, page. 261-267en_US
dc.identifier.issn1738-6756-
dc.identifier.issn2092-9900-
dc.identifier.urihttps://synapse.koreamed.org/DOIx.php?id=10.4048/jbc.2016.19.3.261-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/80753-
dc.description.abstractPurpose: There is no standard targeted therapy for the treatment of triple-negative breast cancer (TNBC). Therefore, its management heavily depends on adjuvant chemotherapy. Using core needle biopsy, this study evaluated the histological factors of TNBC predicting the response to chemotherapy. Methods: One hundred forty-three TNBC patients who received single-regimen neoadjuvant chemotherapy (NAC) with the combination of doxorubicin, cyclophosphamide, and docetaxel were enrolled. The core needle biopsy specimens acquired before NAC were used to analyze the clinicopathologic variables and overall performance of the predictive model for therapeutic response. Results: Independent predictors of pathologic complete response after NAC were found to be higher number of tumor infiltrating lymphocytes (p=0.007), absence of clear cytoplasm (p= 0.008), low necrosis (p=0.018), and high histologic grade (p=0.039). In the receiver operating characteristics curve analysis, the area under curve for the combination of these four variables was 0.777. Conclusion: The present study demonstrated that a predictive model using the above four variables can predict therapeutic response to single-regimen NAC with the combination of doxorubicin, cyclophosphamide, and docetaxel in TNBC. Therefore, adding these morphologic variables to clinical and genomic signatures might enhance the ability to predict the therapeutic response to NAC in TNBC.en_US
dc.description.sponsorshipThis study was supported by a research grant (2013-15) from Jeju National University Hospital in 2013.en_US
dc.language.isoenen_US
dc.publisherKOREAN BREAST CANCER SOCen_US
dc.subjectCore needle biopsyen_US
dc.subjectNeoadjuvant therapyen_US
dc.subjectTreatment outcomeen_US
dc.subjectTriple-negative breast neoplasmsen_US
dc.titleHistomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.en_US
dc.typeArticleen_US
dc.identifier.doi10.4048/jbc.2016.19.3.261-
dc.relation.journalJOURNAL OF BREAST CANCER-
dc.contributor.googleauthorJung, Yoon Yang-
dc.contributor.googleauthorHyun, Chang Lim-
dc.contributor.googleauthorJin, Min-Sun-
dc.contributor.googleauthorPark, In Ae-
dc.contributor.googleauthorChung, Yul Ri-
dc.contributor.googleauthorShim, Bobae-
dc.contributor.googleauthorLee, Kyu Ho-
dc.contributor.googleauthorRyu, Han Suk-
dc.relation.code2016011435-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidyunshallow-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE